JP2007509607A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509607A5
JP2007509607A5 JP2006530599A JP2006530599A JP2007509607A5 JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5 JP 2006530599 A JP2006530599 A JP 2006530599A JP 2006530599 A JP2006530599 A JP 2006530599A JP 2007509607 A5 JP2007509607 A5 JP 2007509607A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid construct
antigen
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006530599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509607A (ja
JP4814099B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2004/004279 external-priority patent/WO2005035771A2/en
Publication of JP2007509607A publication Critical patent/JP2007509607A/ja
Publication of JP2007509607A5 publication Critical patent/JP2007509607A5/ja
Application granted granted Critical
Publication of JP4814099B2 publication Critical patent/JP4814099B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006530599A 2003-10-10 2004-10-11 核酸構築物 Expired - Fee Related JP4814099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50993603P 2003-10-10 2003-10-10
US60/509,936 2003-10-10
PCT/GB2004/004279 WO2005035771A2 (en) 2003-10-10 2004-10-11 Nucleic acid constructs

Publications (3)

Publication Number Publication Date
JP2007509607A JP2007509607A (ja) 2007-04-19
JP2007509607A5 true JP2007509607A5 (enExample) 2007-12-06
JP4814099B2 JP4814099B2 (ja) 2011-11-09

Family

ID=34435038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530599A Expired - Fee Related JP4814099B2 (ja) 2003-10-10 2004-10-11 核酸構築物

Country Status (21)

Country Link
US (1) US8663657B2 (enExample)
EP (1) EP1685251B1 (enExample)
JP (1) JP4814099B2 (enExample)
KR (2) KR101234981B1 (enExample)
CN (1) CN1890375B (enExample)
AU (1) AU2004279991B2 (enExample)
BR (1) BRPI0415204A (enExample)
CA (1) CA2542288A1 (enExample)
DK (1) DK1685251T3 (enExample)
EA (1) EA010056B1 (enExample)
ES (1) ES2457022T3 (enExample)
IL (1) IL174848A (enExample)
MX (1) MXPA06003978A (enExample)
NO (1) NO20062080L (enExample)
NZ (1) NZ546554A (enExample)
PL (1) PL1685251T3 (enExample)
PT (1) PT1685251E (enExample)
SG (1) SG147430A1 (enExample)
SI (1) SI1685251T1 (enExample)
WO (1) WO2005035771A2 (enExample)
ZA (1) ZA200603685B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
CA2624615A1 (en) * 2005-10-05 2007-04-19 Bayhill Therapeutics, Inc. Compositions and methods for treatment of autoimmune disease
PT2310501E (pt) 2008-07-23 2013-07-18 Boehringer Ingelheim Pharma Novos elementos reguladores
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
CN101993878B (zh) * 2010-10-14 2012-04-18 南京农业大学 一种rRNA嵌合启动子及含有该嵌合启动子的表达载体
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
ES2969742T3 (es) * 2012-03-27 2024-05-22 CureVac SE Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
RU2651498C2 (ru) * 2012-03-27 2018-04-19 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты
BR112014023898A2 (pt) * 2012-03-27 2017-07-11 Curevac Gmbh moléculas de ácido nucleico artificiais compreendendo 5''utr top
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
DK2711426T3 (en) * 2012-09-24 2015-07-13 Lonza Biologics Plc Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
EP2938725B1 (en) 2012-12-31 2017-08-23 Boehringer Ingelheim International GmbH Heterologous intron within an immunoglobulin domain
WO2014102101A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102104A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Artificial introns
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) * 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
CN103901209B (zh) * 2014-02-18 2016-05-25 王明丽 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
WO2015195049A1 (en) * 2014-06-18 2015-12-23 Agency For Science, Technology And Research Novel promoters for high level expression
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
US20200377887A1 (en) * 2017-09-22 2020-12-03 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1995019799A1 (en) 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
CA2224724C (en) * 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
GB9715064D0 (en) 1997-07-17 1997-09-24 Ppl Therapeutics Scotland Ltd Protein expression
US20020106635A1 (en) 1998-05-27 2002-08-08 Bruce Freimark Cytokine resistant cytomegalovirus promoter mutants and related products and methods
AU766005B2 (en) * 1998-10-19 2003-10-09 Powderject Vaccines, Inc. Minimal promoters and uses thereof
WO2001058483A2 (en) 2000-02-08 2001-08-16 The University Of Virginia Patent Foundation METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US20030124523A1 (en) * 2000-06-22 2003-07-03 Asselbergs Fredericus Alphonsus Maria Organic compounds
CN1247785C (zh) * 2000-10-13 2006-03-29 希龙公司 巨细胞病毒内含子a片段
KR20040045391A (ko) 2000-11-27 2004-06-01 파우더젝트 백신, 인코포레이티드 핵산 어쥬번트
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2002094313A2 (en) * 2001-05-18 2002-11-28 Powderject Vaccines, Inc. Vaccine composition
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
EP1675596A4 (en) 2003-10-10 2009-01-21 Powderject Vaccines Inc METHOD
GB0507997D0 (en) 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs

Similar Documents

Publication Publication Date Title
JP2007509607A5 (enExample)
JP6903120B2 (ja) アルファウイルスワクチン接種のための組成物及び方法
JP2025084808A (ja) エプスタイン－バーウイルスワクチン
CN104884082B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
Qi et al. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection
CN116390752A (zh) 自扩增性sars-cov-2rna疫苗
US6831169B2 (en) Hepatitis C virus vaccine
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
WO2000011140A1 (en) Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
CA2447450A1 (en) Corona-virus-like particles comprising functionally deleted genomes
JP2021509107A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用
JP2008528020A (ja) 核酸構築物
CN101573449A (zh) 用于治疗慢性乙型肝炎的dna疫苗及其制备方法
CN114729010B (zh) 乙型肝炎病毒疫苗
WO2022077591A1 (zh) 一种重组腺病毒在制备预防病毒的药物中的用途
WO2020254876A1 (en) Virus-like particle delivery of hepatitis b virus (hbv) vaccines
CN118791633A (zh) 一种预防病毒性心肌炎的细菌样颗粒疫苗及其制备方法和应用
WO2020255015A1 (en) Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
Zhou et al. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine
CN103239717B (zh) 治疗慢性乙型肝炎的复制子dna疫苗
JP2023546603A (ja) 外来抗原をコードする遺伝物質を含む、ターゲット組織の大きさまたは体積の縮小用のワクチン組成物またはキット
WO2004072274A1 (en) Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
US20240335531A1 (en) Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
EP4574168A1 (en) Prime-boost immunization against influenza
Shiau et al. Analysis of Humoral Immunity of Hepatitis D Virus DNA Vaccine Generated in Mice by Using Different Dosage, Gene Gun Immunization, andIn VivoElectroporation